Log In
BCIQ
Print this Print this
 

biosimilar filgrastim (Grastofil)

  Manage Alerts
Collapse Summary General Information
Company Apotex Inc.
DescriptionBiosimilar of Neupogen filgrastim
Molecular Target
Mechanism of ActionBiosimilar
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentApproved
Standard IndicationNeutropenia
Indication DetailsTreat neutropenia
Regulatory Designation
PartnerStada Arzneimittel AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/04/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today